Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Lymphoma 9Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 6Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 3Melanoma 3Lymphoma, B-Cell 3Hodgkin Disease 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Multiple Myeloma 2Lymphoproliferative Disorders 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Sezary Syndrome 1Sarcoma, Clear Cell 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mycosis Fungoides 1Microsatellite Instability 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 2fludarabine 1epacadostat 1atezolizumab 1aldesleukin 1Nivolumab 1Interleukin-2 1Cyclophosphamide 1Carboxylesterase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × atezolizumab × Lymphoid × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡